HeartBeam Inc. (NASDAQ: BEAT) Combats Rising Heart Disease Numbers by Leading Out in Heart-Attack Detection Space
- Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly
- HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution
- “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO
With heart disease consistently being the leading cause of death in the United States (https://nnw.fm/m9Kcs ), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution.
HeartBeam’s efforts appear even more important looking forward. A recent Science Daily article (https://nnw.fm/QJyiF ) reported that “by the year 2060, projected rates of cardiovascular risk factors and disease will increase significantly in the United States, according to a study published today in the Journal of the American College of Cardiology. Substantial increases in cardiovascular trends may contribute to a rising burden on the U.S. health care system and highlight the need for equitable access to prevention education and treatments now to prevent future disease.”
Major cardiovascular (“CV”) risk factors include unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. “Among the general U.S. population, all four CV risk factors are expected to increase from 2025 to 2060,” the article continued. “The researchers found that stroke (33.8% to 15M) and heart failure (33.4% to 13M) were the highest projected increases in rates of cardiovascular diseases, followed by ischemic heart disease (30.7% to 29M) and heart attack (16.9% to 16M).”
HeartBeam is focused on those rising heart attack numbers. The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack, and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection.
“Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” stated HeartBeam CEO and founder Branislav Vajdic, PhD (https://nnw.fm/UPE1o ). “By providing remote, 12-lead 3D vector ECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting.”
The company anticipates receiving regulatory approval soon for the use of the HeartBeam AIMI system in acute-care settings. In a recent report to shareholders, Vajdic noted that the company is in discussions with the FDA and expects the system to be cleared in Q1 2023. In an emergency situation, the software will provide an attending physician with an instant comparison of the patient’s baseline and symptomatic ECG along with diagnostic suggestions, enabling medical care providers to quickly determine if a patient needs intervention or can be discharged, which helps manage ED capacity. The company is planning to submit the first version of HeartBeam AIMIGo to the FDA in Q1 2023 as well.
For more information, visit the company’s website at www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Rates of cardiovascular risk factors, disease and heart attacks projected to increase significantly
- HeartBeam offers a personal, portable and easy-to-use heart-attack detection solution
- “Our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” states CEO
With heart disease consistently being the leading cause of death in the United States (https://nnw.fm/m9Kcs ), companies such as HeartBeam (NASDAQ: BEAT) that are focusing on solutions are gaining both attention and support. As a cardiac technology company, HeartBeam is leading the way in identifying heart attacks by developing a personal, portable and easy-to-use heart-attack detection solution.
HeartBeam’s efforts appear even more important looking forward. A recent Science Daily article (https://nnw.fm/QJyiF ) reported that “by the year 2060, projected rates of cardiovascular risk factors and disease will increase significantly in the United States, according to a study published today in the Journal of the American College of Cardiology. Substantial increases in cardiovascular trends may contribute to a rising burden on the U.S. health care system and highlight the need for equitable access to prevention education and treatments now to prevent future disease.”
Major cardiovascular (“CV”) risk factors include unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. “Among the general U.S. population, all four CV risk factors are expected to increase from 2025 to 2060,” the article continued. “The researchers found that stroke (33.8% to 15M) and heart failure (33.4% to 13M) were the highest projected increases in rates of cardiovascular diseases, followed by ischemic heart disease (30.7% to 29M) and heart attack (16.9% to 16M).”
HeartBeam is focused on those rising heart attack numbers. The company has two patented products in development: HeartBeam AIMI(TM), software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack, and HeartBeam AIMIGo(TM), the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection.
“Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks,” stated HeartBeam CEO and founder Branislav Vajdic, PhD (https://nnw.fm/UPE1o ). “By providing remote, 12-lead 3D vector ECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting.”
The company anticipates receiving regulatory approval soon for the use of the HeartBeam AIMI system in acute-care settings. In a recent report to shareholders, Vajdic noted that the company is in discussions with the FDA and expects the system to be cleared in Q1 2023. In an emergency situation, the software will provide an attending physician with an instant comparison of the patient’s baseline and symptomatic ECG along with diagnostic suggestions, enabling medical care providers to quickly determine if a patient needs intervention or can be discharged, which helps manage ED capacity. The company is planning to submit the first version of HeartBeam AIMIGo to the FDA in Q1 2023 as well.
For more information, visit the company’s website at www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
